HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

regimen over a period of 48 weeks. Results from the SOLO trial were presented in November 2002 at the 6th International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

NEAT was a phase III, randomized, open-label, parallel-group 48-week study that compared 908 BID and nelfinavir BID, both in combination with ABC and 3TC in 249 antiretroviral therapy-nave patients. The primary endpoint of the NEAT study was the proportion of subjects with vRNA <400 c/mL at 24 and 48 weeks. Interim 24-week data from NEAT were presented in September at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICACC) in San Diego, and 48-week data are being presented here today.

Once approved, GSK will market 908 and GSK and Vertex will co-promote it in the United States and key markets in Europe.

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.

This press release may contain forward-looking statements, including that 48-week interim analysis of the NEAT and SOLO studies in GlaxoSmithKline's pivotal program for 908 is indicative of a promising clinical and commercial outlook for 908, once approved. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. These risks and uncertainties include, among other things, the risk that approval will be delayed or will not be obtained, that 908 will not be commercially successful, and those other risks listed under Risk Factors in Vertex's form 10-K filed with the Securities and Exchange Commission on April 1, 2002.


'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... – Temple University School of Medicine announced today ... an initiative funded by the Bill & Melinda ... of Obstetrics, Gynecology and Reproductive Sciences; and Vice ... University School of Medicine will pursue an innovative ... Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... 25, 2014 Silicon Valley Electronic Data ... RPM Alliance , provider of clinical research and ... the latest addition to its CRO Partnership Program, Clinovo ... system to India. , “We have found Clinovo’s ... customizable EDC platform which is both user friendly and ...
(Date:11/26/2014)... Chester, OH (PRWEB) November 25, 2014 ... Holdings, has joined the Graphel Carbon Products team as ... in sales, marketing, and customer service for the graphite ... add Miles to our team,” stated Dave Trinkley, VP ... “His wide range of experience in the graphite ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
Cached News: